ACET
Adicet Bio, Inc. NASDAQ Listed Jan 26, 2018$8.10
+0.00%
vs $8.10
Mkt Cap $55.8M
52w Low $6.11
18.9% of range
52w High $16.64
50d MA $7.94
200d MA $9.26
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.1x
ROE
-73.4%
P/FCF
-0.6x
RSI (14)
36.00
ATR (14)
$0.48
Beta
1.58
50d MA
$7.94
200d MA
$9.26
Avg Volume
103.1K
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
200 Clarendon Street · Boston, MA 02116 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -3.23 | -2.94 | +9.0% | 7.04 | -0.9% | +2.4% | -0.6% | +0.3% | -3.6% | +2.0% | — |
| Nov 5, 2025 | AMC | -4.16 | -4.64 | -11.5% | 11.04 | +0.0% | -1.9% | -5.5% | +2.7% | -1.6% | +6.2% | — |
| Aug 7, 2025 | AMC | -5.12 | -5.44 | -6.2% | 10.99 | -1.0% | -9.6% | -4.0% | +7.1% | +7.4% | -5.3% | — |
| May 6, 2025 | AMC | -5.44 | -4.96 | +8.8% | 9.64 | -0.4% | -18.6% | -2.5% | +27.6% | +18.2% | -7.4% | — |
| Mar 6, 2025 | AMC | -5.92 | -5.12 | +13.5% | 13.54 | -3.1% | -5.9% | -4.2% | +3.4% | +0.6% | -2.3% | — |
| Nov 6, 2024 | AMC | -5.76 | -5.44 | +5.6% | 20.80 | +0.0% | +2.3% | -1.5% | -3.8% | -4.8% | -5.0% | — |
| Aug 13, 2024 | AMC | -5.60 | -5.28 | +5.7% | 20.80 | +1.5% | +5.4% | +4.4% | +7.0% | +1.3% | -5.2% | — |
| May 14, 2024 | AMC | -5.60 | -5.60 | +0.0% | 21.28 | +6.0% | +5.3% | +12.1% | +1.9% | +1.2% | -0.6% | — |
| Mar 19, 2024 | AMC | -11.52 | -11.04 | +4.2% | 32.48 | +9.4% | +5.4% | -4.7% | +7.4% | +0.5% | +1.8% | — |
| Nov 8, 2023 | AMC | -11.68 | -11.36 | +2.7% | 21.28 | -2.3% | -6.0% | -4.0% | -1.7% | +0.0% | +2.5% | — |
| Aug 9, 2023 | AMC | -10.88 | -12.00 | -10.3% | 33.60 | -4.3% | +11.9% | -2.1% | -7.0% | -0.5% | -3.3% | — |
| May 9, 2023 | AMC | -11.84 | -11.52 | +2.7% | 107.68 | +3.4% | +3.0% | -3.9% | -4.5% | +12.1% | -4.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Jefferies | Reiterates | Buy | $19 | $8.45 | $8.61 | +1.9% | +0.7% | +0.5% | -2.7% | +2.8% | -4.4% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.92 | $6.82 | -1.4% | -3.8% | +0.5% | +1.8% | -1.2% | -3.9% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $7.04 | $6.98 | -0.9% | +2.4% | -0.6% | +0.3% | -3.6% | +2.0% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.90 | $8.13 | +2.9% | +2.2% | +4.1% | +0.5% | +3.1% | -1.8% |
| Jan 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.15 | $8.10 | -0.6% | -1.2% | +5.0% | -4.3% | -0.7% | -2.7% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.83 | $10.72 | -1.0% | -5.5% | +2.7% | -1.6% | +6.2% | -3.4% |
| Oct 8 | Guggenheim | Maintains | Buy → Buy | — | $13.65 | $13.76 | +0.8% | +8.9% | -1.5% | +5.8% | +1.2% | -2.0% |
| Sep 19 | Guggenheim | Maintains | Buy → Buy | — | $12.97 | $13.12 | +1.2% | -1.9% | +3.2% | +1.1% | +3.0% | -1.9% |
| Mar 21 | Guggenheim | Maintains | Buy → Buy | — | $12.23 | $12.23 | +0.0% | +0.2% | +19.3% | -3.2% | +1.3% | -5.2% |
| Mar 7 | Citizens Capital Markets | Maintains | Market Perform → Market Perform | — | $13.54 | $13.12 | -3.1% | -5.9% | -4.2% | +3.4% | +0.6% | -2.3% |
| Mar 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.54 | $13.12 | -3.1% | -5.9% | -4.2% | +3.4% | +0.6% | -2.3% |
| Feb 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $14.44 | $14.76 | +2.2% | -4.8% | +4.6% | -5.7% | +2.8% | +0.4% |
| Feb 6 | JMP Securities | Maintains | Market Perform → Market Perform | — | $16.16 | $15.68 | -3.0% | +2.0% | -6.3% | -6.7% | +0.1% | -3.9% |
| Feb 5 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $14.72 | $15.97 | +8.5% | +9.8% | +2.0% | -6.3% | -6.7% | +0.1% |
| Dec 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $14.33 | $14.72 | +2.7% | -4.0% | +5.8% | -1.8% | +2.5% | +4.8% |
| Aug 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $20.80 | $21.12 | +1.5% | +5.4% | +4.4% | +7.0% | +1.3% | -5.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.80 | $21.12 | +1.5% | +5.4% | +4.4% | +7.0% | +1.3% | -5.2% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.12 | $19.20 | +12.1% | +9.3% | +3.4% | +5.0% | -0.8% | -4.0% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.92 | $22.40 | +2.2% | +9.5% | -2.0% | -8.8% | +0.0% | -9.7% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.76 | $22.88 | +5.1% | +5.9% | -2.8% | -3.6% | -3.0% | -1.5% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.28 | $22.56 | +6.0% | +5.3% | +12.1% | +1.9% | +1.2% | -0.6% |
| Apr 23 | Wedbush | Maintains | Outperform → Outperform | — | $32.00 | $34.24 | +7.0% | +5.0% | -10.5% | -3.7% | -7.2% | -5.4% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.40 | $37.60 | -2.1% | -1.7% | -4.2% | +0.9% | -1.3% | -3.1% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.48 | $35.52 | +9.4% | +5.4% | -4.7% | +7.4% | +0.5% | +1.8% |
| Mar 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $32.48 | $35.52 | +9.4% | +5.4% | -4.7% | +7.4% | +0.5% | +1.8% |
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $32.48 | $35.52 | +9.4% | +5.4% | -4.7% | +7.4% | +0.5% | +1.8% |
| Feb 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.44 | $48.80 | -1.3% | -2.9% | +4.0% | +2.2% | +0.6% | +5.3% |
| Jan 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $34.56 | $33.76 | -2.3% | +12.0% | +1.7% | +40.2% | -2.9% | -9.3% |
| Nov 9 | Wedbush | Maintains | Outperform → Outperform | — | $21.28 | $20.80 | -2.3% | -6.0% | -4.0% | -1.7% | +0.0% | +2.5% |
| Sep 6 | Truist | Maintains | Buy → Buy | — | $29.76 | $29.44 | -1.1% | -2.7% | -1.7% | -5.1% | +0.6% | -5.9% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.60 | $36.80 | -2.1% | -2.1% | -7.0% | -0.5% | -3.3% | -4.4% |
| Aug 10 | Wedbush | Maintains | Outperform → Outperform | — | $33.60 | $32.16 | -4.3% | +11.9% | -2.1% | -7.0% | -0.5% | -3.3% |
| Aug 10 | BTIG | Maintains | Buy → Buy | — | $33.60 | $32.16 | -4.3% | +11.9% | -2.1% | -7.0% | -0.5% | -3.3% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $74.56 | $61.44 | -17.6% | -54.3% | +23.9% | -12.5% | +5.2% | +12.3% |
| Jun 27 | Guggenheim | Downgrade | Buy → Neutral | — | $74.56 | $61.44 | -17.6% | -54.3% | +23.9% | -12.5% | +5.2% | +12.3% |
| Jun 27 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $74.56 | $61.44 | -17.6% | -54.3% | +23.9% | -12.5% | +5.2% | +12.3% |
| Jun 1 | JP Morgan | Downgrade | Overweight → Neutral | — | $87.68 | $81.60 | -6.9% | -5.1% | +2.9% | -1.7% | +1.1% | +7.3% |
| May 15 | JMP Securities | Maintains | Market Outperform → Outperform | — | $101.76 | $102.40 | +0.6% | +12.1% | -4.2% | -2.3% | -3.1% | -2.8% |
| May 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $101.76 | $102.40 | +0.6% | +12.1% | -4.2% | -2.3% | -3.1% | -2.8% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $107.68 | $111.36 | +3.4% | +3.0% | -3.9% | -4.5% | +12.1% | -4.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $107.68 | $111.36 | +3.4% | +3.0% | -3.9% | -4.5% | +12.1% | -4.2% |
| Mar 16 | Wedbush | Maintains | Outperform → Outperform | — | $123.36 | $118.88 | -3.6% | +0.0% | -3.6% | -13.7% | +2.5% | -9.0% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $123.36 | $118.88 | -3.6% | +0.0% | -3.6% | -13.7% | +2.5% | -9.0% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $276.32 | $173.60 | -37.2% | -39.6% | +3.5% | -1.4% | -6.5% | -5.5% |
| Sep 21 | JP Morgan | Maintains | Overweight → Overweight | — | $236.96 | $244.64 | +3.2% | -3.5% | -4.4% | +1.8% | -0.8% | -0.3% |
| Mar 31 | SMBC Nikko | Maintains | Outperform → Outperform | — | $313.12 | $314.24 | +0.4% | +2.0% | +4.2% | -4.9% | -2.9% | +0.8% |
| Mar 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $255.04 | $249.76 | -2.1% | +1.9% | -0.9% | -6.1% | +10.8% | -1.2% |
| Mar 8 | Truist | Maintains | Buy → Buy | — | $200.96 | $207.52 | +3.3% | +4.1% | +9.6% | -1.5% | -7.1% | -6.3% |
| Mar 4 | Jefferies | Maintains | Buy → Buy | — | $196.96 | $201.60 | +2.4% | +2.0% | +0.0% | +4.1% | +9.6% | -1.5% |
| Dec 6 | Guggenheim | Maintains | Buy → Buy | — | $156.80 | $218.40 | +39.3% | +38.5% | +6.8% | +5.5% | -10.1% | +1.1% |
No insider trades available.
8-K
Adicet Bio, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this summary as it lacks essential information about the specific executive officer compensation changes or material events at Adicet Bio that would impact investors.
Jun 18
8-K · 2.02
!! High
Adicet Bio, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Adicet's strong Phase 1 enrollment and positive autoimmune therapy data suggest clinical progress that could accelerate pipeline advancement and reduce development risk, making the stock attractive for investors betting on gamma delta T-cell therapy success.
Mar 12
Institutional (13F) — Top 1
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Regeneron Pharmaceuticals, Inc. | 60,511 | $412K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$55.8M
Enterprise Value
-$102.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
0.35x
P/S
—
P/FCF
-0.58x
EV/EBITDA
—
Shares Out
6.9M
Financials (TTM)
Revenue
$0
Net Income
-$108.8M
EBITDA
-$102.7M
Free Cash Flow
-$97.0M
Op Cash Flow
-$95.2M
EPS Basic
$-16.95
EPS Diluted
$-14.90
EPS Forward
$-32.05
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$192.4M
Total Liab.
$33.1M
Total Equity
$159.2M
Cash
$158.5M
LT Debt
$0
Book Value/Sh
$23.10
Debt/Equity
0.09x
Current Ratio
7.47
Quick Ratio
7.47
Returns & Growth
ROE
-73.4%
ROA
-60.7%
ROIC
-70.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+20.3%
Price Returns
2W
+10.7%
1M
+23.3%
3M
+28.4%
6M
-10.2%
12M
-19.0%
Technicals
52W High
$16.64
52W Low
$6.11
50d MA
$7.94
200d MA
$9.26
RSI (14)
36.00
ATR (14)
$0.48
Beta
1.58
Avg Volume
103K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$18.00
High
$18.00
Low
$18.00
Median
$18.00
Data updated apr 24, 2026 10:28am
· Source: financialmodelingprep.com